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A predictive marker of the rapid progression to hepatic failure is desired for patients with asymptom-
atic primary biliary cirrhosis (aPBC).  We performed a systematic cohort analysis of 101 patients 
diagnosed as having aPBC and the rapid progression to liver failure in some,  by focusing on cholesta-
sis.  Cholestasis was assessed by aberrant keratin7 (K-7) expressions in the patientsʼ hepatocytes.  
Intralobular expressions of K-7 were found in 9 of the 101 patients.  The grades of K-7 expression 
were signiﬁcantly associated with the levels of alanine aminotransferase,  alkaline phosphatase,  and 
total bilirubin at the time of diagnosis,  but not with bile duct loss or cholestasis.  Stepwise logistic 
regression analysis revealed that high grades of K-7 expression correlated positively with high levels 
of total bilirubin.  During the follow-up period,  8 patients developed jaundice,  and the mean period 
until the development of jaundice was 5.2 years.  The proportional hazards models for the risk of 
developing jaundice identiﬁed a high grade of aberrant K-7 expression in hepatocytes as the only sig-
niﬁcant risk factor.  Aberrant K-7 expression in hepatocytes can be used as an additional marker to 
predict rapid progression to liver failure in patients with aPBC at the time of diagnosis.
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rimary biliary cirrhosis (PBC) is a chronic 
cholestatic disease characterized by the pro-
gressive destruction of small septal and interlobular 
bile ducts [1-3].  The recent emphasis on routine 
testing for biliary enzymes and anti-mitochondrial 
antibodies has increased the number of newly diag-
nosed cases of PBC without disease-related symptoms 
[4-6].  A signiﬁcant proportion of these patients are 
in the early disease stage,  and the prognosis of 
elderly asymptomatic patients is likely to be as good 
as that of age- and gender-matched controls from the 
general population [6].  Regarding the progression of 
PBC,  at least 2 diﬀerent types of progression in PBC 
have been proposed; one is a hepatic failure-type 
progression,  in which the patients develop rapid pro-
gression to end-stage hepatic failure even when they 
are properly medicated with ursodeoxycholic acid and 
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bezaﬁbrate,  and the other is a portal hypertension-
type progression,  in which patients develop complica-
tions of portal hypertension such as esophageal varices 
in the early disease stage without jaundice [7-9].
　 The histological staging of PBC patients has been 
reported by Scheuer et al.  [10].  However,  there have 
been some diﬃculties in the staging of PBC because 
the grading of cholestasis is not included in this clas-
siﬁcation.  Cholestasis and inﬂammatory activity in the 
portal tract are independent events,  and the progres-
sion of liver damage in PBC is caused by cholestasis 
and periportal inﬂammation.  Nakanuma et al.  proposed 
a new histological classiﬁcation which separately 
evaluates the grade of cholestasis,  the loss of bile 
ducts,  and periportal inﬂammation in addition to the 
stage of ﬁbrosis [11].  Cholestasis in PBC can be 
detected by the deposition of copper or copper-associ-
ated protein in hepatocytes [12].  We reported that 
the aberrant expression of bile duct-type keratin (K) 7 
in hepatocytes is useful to evaluate the grade of 
cholestasis,  and that the aberrant K-7 expression is 
more sensitive than the deposition of copper-associ-
ated protein [13].
　 In the present study,  we focused on cholestasis in 
hepatocytes,  and investigated the aberrant K-7 
expression in hepatocytes from patients with aPBC.  
The patients were assessed for biochemical data,  
histological classiﬁcations,  and disease prognosis in 
order to clarify whether the K-7 expression can be 
used as an additional marker to predict the rapid 
progression to liver failure in patients with aPBC at 
the time of diagnosis.
Patients and Methods
　 Patients. The diagnosis of PBC was made at 
Okayama University Hospital from 1980 to 2012,  
based on the following criteria: (1) positive test for 
anti-mitochondrial antibody or antinuclear antibody,  
(2) biochemical evidence of cholestasis,  and (3) liver 
biopsy compatible with the diagnosis [14].  Patients 
with overlapping PBC and autoimmune hepatitis with 
severe lobular inﬂammation were excluded.  Patients 
who were serum-positive for hepatitis B surface anti-
gen or anti-hepatitis C virus antibodies,  and those 
with daily ethanol use of more than 80 grams were also 
excluded.  The study was performed in accordance 
with the Helsinki Declaration and was approved by the 
ethical committee of the institution.  All patients pro-
vided informed consent.
　 Of these 150 patients,  histological cirrhosis,  jaun-
dice and/or symptoms of portal hypertension were 
observed in 49 patients at the time of diagnosis.  Thus,  
a total study population of 101 patients who had aPBC 
without histological cirrhosis,  or disease-related 
symptoms of jaundice or portal hypertension was used 
for further analysis.  Jaundice was deﬁned as total 
bilirubin＞2.0mg/dL,  and portal hypertension as 
meeting one of the following criteria: (1) esophageal 
or gastric varices,  (2) splenomegaly,  or (3) platelet 
counts＜100,000/dL.  Anti-gp210 antibodies were 
detected as previously described [8].
　 Histological evaluation. Laparoscopy-assisted 
liver biopsy was done for all patients at the time of 
diagnosis in order to accurately rule out cirrhotic 
patients.  The histological stage was determined 
according to the criteria of Scheuer et al.  [10].  We 
also used a new histological classiﬁcation proposed by 
Nakanuma et al.  [11].  Brieﬂy,  chronic cholangitis with 
mild periductal lymphoplasmacytic inﬁltration,  includ-
ing chronic nonsuppurative destructive cholangitis,  
and the combined activity of interface hepatitis and 
lobular hepatitis were categorized into 4 grades on the 
basis of their degree and distribution (CA0-3 and 
HA0-3,  respectively).  For staging,  cholestasis (evalu-
ated with orcein staining),  ﬁbrosis and bile duct loss 
were independently scored from 0 to 3 on the basis of 
their degrees,  and a ﬁnal stage score was created 
from the sum.
　 Immunohistochemistry of keratin. Immuno-
histochemical analysis was performed using formalin-
ﬁxed paraﬃn-embedded samples at the time of diagno-
sis.  Five-micron sections were cut and deparaﬃnized.  
The sections were treated with 0.05ｵ protease (type 
XXV,  Sigma Aldrich Japan,  Tokyo,  Japan) in a 
50-mM Tris-HCl solution for 10min at room tempera-
ture for antigen retrieval.  The intrinsic peroxidase 
activity was blocked by immersing sections in a metha-
nol solution containing 0.3ｵ hydrogen peroxide.  The 
sections then underwent a reaction with a monoclonal 
antibody for K-7 (OV-TL 12/30,  Dako,  Glostrup,  
Denmark) after nonspeciﬁc binding was blocked with 
casein.  The Envision detection system was equipped 
with DAB (Dako).  For controls,  the ﬁrst monoclonal 
antibody was omitted from the reaction process.  In the 
normal liver,  K-7 expresses only in bile duct epithe-
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lial cells,  whereas livers of PBC patients show vary-
ing degrees of K-7 expression in proliferated bile 
ductules and hepatocytes as well as bile duct epithelial 
cells.  Proliferated bile ductules were markedly pres-
ent at the border between the portal tract and liver 
parenchyma.
　 As previously described [13],  K-7 expression 
patterns were classiﬁed into the following 4 grades 
(Fig.  1): Grade 1,  K-7 expression in bile duct epi-
thelial cells and proliferated bile ductules; Grade 2,  
periportal hepatocytes positive for K-7; Grade 3,  
intralobular hepatocytes also positive for K-7; Grade 
4,  K-7 diﬀusely stained throughout the lobules.
　 Survival. All patients underwent a physical 
exam at least every 3 to 6 months and an endoscopic 
check-up every year of the follow-up period.  Patients 
who had not visited one of our hospitals in the previ-
ous 6 months were contacted by letter or telephone 
and asked to provide details about recent medications 
and disease-related symptoms.  Other hospitals that 
study participants visited were asked for physical 
examination results and medical data.  When patients 
died,  the date and cause of death were recorded.
　 Statistical analysis. Data are expressed as the 
mean±standard deviation or the median with range.  
Patient characteristics at the time of diagnosis were 
compared among groups using the Wilcoxon rank sum 
test or Fisher exact probability test.  Factors associ-
ated with the grade of cholestasis were analyzed by a 
stepwise logistic regression analysis.  Receiver oper-
ating characteristic curves were constructed for clini-
cal characteristics with correlations of the grades of 
aberrant K-7 expression in hepatocytes.  The best 
cut-oﬀ values were determined based on these results,  
and used for further analyses.  Proportional hazards 
models were used to estimate the factors associated 
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Grade 1 Grade 2
Grade 3 Grade 4
Fig. 1　 The grades of aberrant K-7 expression in hepatocytes.  Grade 1: K-7 is expressed only in proliferated bile ductules at the inter-
face between the portal tract and the parenchyma.  Grade 2: K-7 is expressed in periportal hepatocytes as well as in proliferated bile 
ductules in the portal tract.  Grade 3: K-7 is expressed in intralobular hepatocytes.  Grade 4: K-7 is expressed diﬀusely in hepatocytes.
with the development of jaundice during the follow-up 
period in the patients with aPBC,  and the factors 
were selected in a stepwise manner among the signiﬁ-
cant factors in univariate analysis for the multivariate 
analysis.  The incidence of jaundice was determined 
using the Kaplan-Meier method,  and the results were 
compared using the log rank test.  Statistical analyses 
were performed using JMP 9.0 software (SAS 
Institute,  Cary,  NC,  USA).  P-values＜0.05 were 
considered signiﬁcant.
Results
　 Associations of patient characteristics with 
aberrant K-7 expression. The present study 
enrolled 101 patients who were diagnosed as having 
aPBC without histological cirrhosis,  jaundice or 
portal hypertension.  The clinical characteristics and 
pathological features of the patients are listed in 
Table 1.  The majority of the patients were females 
(97 females and 4 males) in their 50s,  which is consis-
tent with previous studies [6].  High grades of aber-
rant K-7 expression in hepatocytes (grades 3 and 4) 
were found in 9 patients (9ｵ).  As shown in Table 2,  
the comparisons of clinical characteristics between the 
patient groups with high and low grades of aberrant 
K-7 expression in hepatocytes revealed that the 
grades of aberrant K-7 expression in hepatocytes 
were not signiﬁcantly associated with the histological 
classiﬁcations such as the PBC stages in the classiﬁ-
cations by Scheuer or Nakanuma,  or the detailed 
parameters of bile duct loss or chronic cholestasis (p
＝0.31,  0.20,  0.23,  and 1.0,  respectively,  the Fisher 
exact probability test).
　 Patients with high grades of aberrant K-7 expres-
sion in hepatocytes had signiﬁcantly higher levels of 
aspartate aminotransferase,  alanine aminotransferase,  
alkaline phosphatase,  and total bilirubin in the serum 
compared to those with low grades of aberrant K-7 
expression in hepatocytes (p＝0.0030,  0.0060,  0.020,  
and 0.0015,  respectively,  the Wilcoxon rank sum 
test).  We also evaluated the positivity of anti-gp210 
antibody of 56 of the PBC patients in the present 
study,  because the positivity of anti-gp210 antibody 
has been reported to be a useful marker for detecting 
PBC patients with poor prognosis.  Patients with 
higher grades of aberrant K-7 expression in hepato-
cytes were 66ｵ positive for the anti-gp210 antibody 
while those with lower grades of aberrant K-7 
expression were only 13ｵ positive (p＝0.068,  the 
Fisher exact probability test).
　 Correlations of grades of aberrant K-7 expression 
in hepatocytes with clinical characteristics are listed 
in Table 3.  Serum liver enzyme levels of aspartate 
aminotransferase,  alanine aminotransferase,  alkaline 
phosphatase,  and total bilirubin showed signiﬁcant 
positive correlations with aberrant K-7 expression in 
hepatocytes by univariate logistic regression analysis.  
Multivariate analysis revealed that high grades of 
aberrant K-7 expression in hepatocytes were signiﬁ-
cantly positively correlated with levels of total biliru-
bin (p＝0.0020,  the stepwise logistic regression 
analysis),  although the cut-oﬀ value of total bilirubin 
was as low as 0.8mg/dL.
　 Development of jaundice among the patients 
with aPBC stages at diagnosis. During the 
follow-up period,  8 patients developed jaundice,  and 
the mean period until the development of jaundice was 
5.2 years (1 to 12 years),  as shown in Fig.  2.  Table 
4 shows the proportional hazards model results for the 
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Table 1　 Clinical characteristics of the patients at the time of 
diagnosis
Patient characteristics
Age (years) 52 (29-76)a
Gender (female/male) 97/4
Follow-up period (years) 11±6.5c
Liver histology (Scheuer, 1/2/3/4) 38/14/49/0
Liver histology (Nakanuma, 1/2/3/4)b 28/50/23/0
Chronic cholangitis activity (0/1/2/3)b 5/12/2/82
Hepatic activity (0/1/2/3)b 58/26/10/7
Fibrosis (0/1/2/3)b 47/23/31/0
Bile duct loss (0/1/2/3)b 54/21/16/10
Cholestasis score (0/1/2/3)b 68/14/5/4
Aberrant K-7 expression (1/2/3/4) 84/8/7/2
Anti-mitochondrial antibody (% positive) 77/96 (80%)
Antinuclear antibody (% positive) 63/96 (66%)
Aspartate aminotransferase (IU/L) 46±28c
Alanine aminotransferase (IU/L) 52±40c
Alkaline phosphatase (IU/L) 297±262c
γ-glutamyl transpeptidase (IU/L) 223±277c
Total bilirubin (mg/dL) 0.7±0.3c
Platelet count (×104/mm3) 23±5.9c
Immunoglobulin G (mg/dL) 1808±505c
Immunoglobulin M (mg/dL) 379±204c
Anti-gp210antibody (% positive) 8/48 (17%)
amedian (range).  bHistological stage classiﬁed by Nakanuma et al. 
[11].  cmean±standard deviation.
risk of developing jaundice.  High grades of aberrant 
K-7 expression in hepatocytes,  and higher levels of 
aspartate aminotransferase,  alanine aminotransferase,  
and alkaline phosphatase at the time of diagnosis 
showed signiﬁcant associations with the development 
of jaundice in the univariate analysis.  A high grade of 
aberrant K-7 expression in hepatocytes was the only 
signiﬁcant risk factor in the multivariate analysis 
(hazards ratio 8.7,  p＝0.019).  Actually,  the patient 
groups of diﬀerent grades of aberrant K-7 expression 
in hepatocytes revealed signiﬁcant diﬀerences in the 
incidence of jaundice by the Kaplan-Meier method (p
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Table 2　 Clinical characteristics of patients stratiﬁed by grades of aberrant K-7 expression in hepatocytes
Aberrant K-7 expression
Grades 1, 2
N＝92
Grades 3, 4
N＝9 P
Age (year) 52±9a 51±10a 0.47
Liver histology (Scheuer, 1, 2/3, 4) 49/43 3/6 0.31
Liver histology (Nakanuma, 1, 2/3, 4)b 73/19 5/4 0.20
Chronic cholangitis activity (0, 1/2, 3)b 15/77 3/6 0.36
Hepatic activity (0, 1/2, 3)b 76/16 8/1 0.58
Fibrosis (0, 1/2, 3)b 65/27 5/4 0.45
Bile duct loss (0, 1/2, 3)b 70/22 5/4 0.23
Chronic cholestasis (0, 1/2, 3)b 74/8 8/1 1.0
Aspartate aminotransferase (IU/L) 42±20a 91±56a 0.0030
Alanine aminotransferase (IU/L) 47±33a 101±68a 0.0060
Alkaline phosphatase (IU/L) 279±255a 477±285a 0.020
γ-glutamyl transpeptidase (IU/L) 218±283a 276±205a 0.12
Total bilirubin (mg/dL) 0.7±0.3a 1.1±0.5a 0.0015
Platelet count (×104/mm3) 23±6a 21±6a 0.70
Immunoglobulin M (mg/dL) 377±207a 408±160a 0.53
Anti-gp210 antibody (positive/negative) 6/45 2/3 0.068
amean±standard deviation.  bHistological stage classiﬁed by Nakanuma et al. [11].
Table 3　 Correlations of aberrant K-7 expression in hepatocytes with patient characteristics
Univariate analysis Multivariate analysis
Odds ratio P Odds ratio P
Age (＜52 years) 2.0 (0.5-8.9) 0.49
Liver histology (Scheuer 3, 4) 2.3 (0.5-9.7) 0.31
Liver histology (Nakanuma 3, 4)a 3.1 (0.75-13) 0.23
Chronic cholangitis activity (2, 3)a 0.58 (0.1-3.2) 0.62
Hepatic activity (2, 3)a Not assessed 1.0
Fibrosis (2, 3)a 1.9 (0.48-7.7) 0.45
Bile duct loss (2, 3)a 2.4 (0.59-9.7) 0.24
Chronic cholestasis (2, 3)a 2.1 (0.39-11) 0.33
Aspartate aminotransferase (ｧ40 IU/L) 10.0 (1.2-83) 0.014
Alanine aminotransferase (ｧ41 IU/L) 9.5 (1.1-79) 0.016 2.9 (0.29-71) 0.38
Alkaline phosphatase (ｧ224 IU/L) 9.5 (1.1-79) 0.016 4.0 (0.43-98) 0.24
γ-glutamyl transpeptidase (ｧ149 IU/L) 2.2 (0.51-9.3) 0.32
Total bilirubin (ｧ0.8mg/dL) 20.3 (2.4-171) 0.0006 14.9 (2.4-289) 0.0020
Platelet count (ｧ22×104/mm3) 0.95 (0.12-7.1) 1.0
Immunoglobulin M (ｧ331mg/dL) 1.0 (0.19-5.2) 1.0
Anti-gp210 antibody (positive) 13.3 (1.0-171) 0.015
aHistological stage classiﬁed by Nakanuma et al. [11].
＜0.001,  the log rank test,  Fig.  2).
Discussion
　 Among asymptomatic PBC patients without histo-
logical cirrhosis,  jaundice,  or portal hypertension,  a 
certain portion of patients progress rapidly to end-
stage hepatic failure.  Since the progression to hepatic 
failure is caused by cholestasis and periportal inﬂam-
mation,  the present study focused on cholestasis in 
hepatocytes at the time of diagnosis by studying aber-
rant K-7 expression in hepatocytes.  Our results 
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Fig. 2　 Development of jaundice in patients with aPBC.  The incidence rate of jaundice during follow-up care was assessed by the 
Kaplan-Meier method for patients with aPBC at the time of diagnosis (A).  The incidence rate of jaundice was calculated for the patient 
groups stratiﬁed by grade of aberrant K-7 expression in hepatocytes (B).
Table 4　 Proportional hazards model for the development of jaundice in the patients with early PBC
Factors
Univariate analysis Multivariate analysis
Hazard ratio
(rangea) P
Hazard ratio
(rangea) P
Age (＜52 year) 5.7 (0.93-104) 0.060 4.3 (0.68-87) 0.13
Liver histology (Scheuer 3, 4) 1.4 (0.30-6.9) 0.69
Liver histology (Nakanuma 3, 4)b 1.3 (0.17-5.5) 0.77
Chronic cholangitis activity (2, 3)b 1.0 (0.16-19) 0.99
Hepatic activity (2, 3)b 0.73 (0.04-4.3) 0.78
Fibrosis (2, 3)b 0.84 (0.12-3.9) 0.84
Bile duct loss (2, 3)b 2.0 (0.39-9.0) 0.38
Chronic cholestasis (2, 3)b 1.7 (0.09-10) 0.63
Aspartate aminotransferase (ｧ40 IU/L) 6.9 (1.2-130) 0.031
Alanine aminotransferase (ｧ41 IU/L) 6.6 (1.1-125) 0.035 1.9 (0.20-46) 0.63
Alkaline phosphatase (ｧ224 IU/L) 7.6 (1.3-144) 0.020 2.8 (0.35-63) 0.37
γ-glutamyl transpeptidase (ｧ149 IU/L) 6.2 (1.1-117) 0.043
Total bilirubin (ｧ0.8mg/dl) 4.5 (0.97-31) 0.055 1.1 (0.11-14) 0.92
Platelet count (ｧ22×104/mm3) 1.6 (0.26-12) 0.62
Immunoglobulin M (ｧ331mg/dl) 3.3 (0.5-65) 0.23
Anti-gp210 antibody (positive) 10.5 (1.0-225) 0.050
K-7 expression (3, 4) 15.7 (3.4-79) 0.0008 8.7 (1.4-85) 0.019
a95% conﬁdence interval.  bHistological stage classiﬁed by Nakanuma et al. [11].
revealed that high grades of aberrant K-7 expression 
in hepatocytes at the time of diagnosis were signiﬁ-
cantly associated with the development of jaundice 
during the follow-up period for the patients with 
aPBC; i.e.,  PBC without histological cirrhosis,  jaun-
dice,  or portal hypertension.  This predictive impor-
tance of aberrant K-7 expression in hepatocytes is 
independent from biochemical parameters and histo-
logical classiﬁcations.  Aberrant K-7 expression in 
hepatocytes can be used as an additional marker to 
predict a rapid progression to liver failure in patients 
with aPBC at the time of diagnosis.
　 Keratin is an intermediate ﬁlament and is divided 
into several subtypes.  The type of keratin is speciﬁc 
to the cell lineage.  In the normal liver,  hepatocytes 
and bile duct epithelial cells express a distinct type of 
keratin [15-17].  Bile duct epithelial cells and reac-
tive ductule cells express keratins 7 and 19.  A recent 
report by Khan et al.  demonstrated that K-19 expres-
sion could detect loss of the canals of Hering,  and they 
suggested that this “minimal change” feature may sup-
port a clinical diagnosis of PBC even in the absence of 
characteristic,  granulomatous,  duct-destructive lesions 
[18].
　 On the other hand,  in certain disease conditions 
such as various cholestatic diseases including PBC and 
alcoholic liver disease,  groups of hepatocytes express 
K-7 and K-19 [15].  These aberrant expressions of 
K-7 and K-19 in hepatocytes are dependent on the 
grade and duration of cholestasis,  and are associated 
with the progression of cholestasis [19].  Aberrant 
K-7 expression in hepatocytes is shown to be more 
sensitive than that of K-19 for this purpose.  We 
therefore used K-7 for the evaluation of cholestasis in 
the present study.
　 Our results revealed signiﬁcant positive correla-
tions of the grade of aberrant K-7 expression in 
hepatocytes with the serum levels of total bilirubin and 
alanine aminotransferase.  Since none of the patients 
enrolled in the present study had jaundice with total 
bilirubin＜2.0mg/dL,  aberrant K-7 expression in 
hepatocytes might be used as a sensitive marker of 
cholestasis.  Further assessments of bilirubin levels 
might provide a clinical cut-oﬀ for estimating cholesta-
sis in hepatocytes of PBC patients.  However,  in the 
present study the serum levels of alkaline phosphatase 
did not show signiﬁcant associations with the grade of 
aberrant K-7 expression in hepatocytes.  We reported 
that a high level of alkaline phosphatase at the time of 
diagnosis suggests portal inﬂammation in patients with 
early PBC [9].  Serum levels of alkaline phosphatase 
are indirectly associated with cholestasis,  and might 
not necessarily represent the grade of cholestasis.
　 Several drugs have been used to slow the disease 
progression in PBC patients,  with variable results.  
Our present data are not suﬃcient to assess the ben-
eﬁts of those drugs for suppressing the development 
of jaundice.  However,  our results suggest that 
patients with aberrant K-7 expression in hepatocytes 
need more aggressive therapy to avoid rapid progres-
sion to liver failure.  Further study on the eﬃcacy of 
medication to improve cholestasis in the liver is 
needed for patients with aPBC.
　 In conclusion,  aberrant K-7 expression in hepato-
cytes may provide additional information for the pre-
cise histological grading of PBC and can be used as an 
additional marker to predict rapid progression to liver 
failure in patients with aPBC at the time of diagnosis.
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